Anbio Biotechnology Class A Ordinary Shares (NNNN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 4 | 24 | 7 | 8 | 9 | 12 | - |
| Operating profit | $m | 6 | 8 | ||||||
| Net profit | $m | - | 3 | 10 | 2 | 2 | 6 | 8 | - |
| EPS reported | $ | 0.16 | 0.19 | ||||||
| Operating cashflow per share | $ | -0.15 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.15 | 0.00 | ||||||
| Free cash flow | $m | -7 | 0 | ||||||
| Net debt | $m | -12 | -12 | ||||||
| Book value equity | $m | 30 | 30 | ||||||
| Book value per share | $ | 0.69 | 0.69 | ||||||
| Number of shares | m | 43.89 | 43.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 187.94 | - | ||||||
| P/B LTM | x | 43.77 | 43.77 | ||||||
| P/S LTM | x | 152.63 | 112.08 | ||||||
| P/FCF LTM | x | -195.84 | 0.00 | ||||||
| EV/EBITDA LTM | x | 227.48 | 202.56 | ||||||
| EV/Sales LTM | x | 151.74 | 31.92 | ||||||
| Earnings Yield LTM | % | +0.53% | +2.21% | ||||||
| FCF Yield | % | -0.51% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | +21.24% | +27.49% | ||||||
| ROIC | % | +19.13% | +25.46% | ||||||
| Operating margin | % | +66.70% | +65.20% | ||||||
| Gross margin | % | +87.24% | +86.10% | ||||||
| FCF/Sales | % | -77.94% | 0.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +185.71% | +239.29% | ||||||
| Sales Growth YoY | % | +5.64% | +43.87% | ||||||
| Net Income Growth YoY | % | +169.86% | +257.78% | ||||||
| FCF Growth | % | - | -100.00% | ||||||
| Operating Profit Growth | % | +189.06% | +284.76% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | -1.35 | -1.20 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.39 | -0.39 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Anbio Biotechnology Class A Ordinary Shares (NNNN)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free